Etoposide Pfizer

Etoposide Pfizer





Zuellig Pharma


Concise Prescribing Info
Small cell lung carcinoma, acute monocytic & myelomonocytic leukaemia, Hodgkin's & non-Hodgkin's disease.
Dosage/Direction for Use
Adult 50-60 mg/m2 daily by slow IV infusion over 30-60 min for 5 consecutive days followed by treatment-free interval of 2-3 wk. Total dose: Not to exceed 400 mg/m2/course.
Hypersensitivity. Severe bone marrow failure (WBC <2 x 109/L or platelet count <75 x 109/L) not due to malignant disease; acute infections. Severe hepatic dysfunction. Pregnancy & lactation.
Special Precautions
Anaphylactoid reactions. Not to be administered by intrapleural or intraperitoneal inj. Myelosuppression; bone marrow suppression. Viral, bacterial, fungal &/or parasitic infections. Secondary leukemia; epilepsy; alcoholism; hyperuricemia. Frequently monitor hematologic function during & after therapy. Perform complete blood counts, hepatic & renal function tests & serum urate prior to initiation & before each subsequent course of treatment. Avoid rapid IV infusion & extravasation. Avoid use w/ live vaccines. Hepatic disease. Renal & hepatic impairment. Women of childbearing potential. May impair fertility in men. Not to be used during pregnancy & lactation. Childn & premature infants. Elderly.
Adverse Reactions
Bone marrow suppression; cardiotoxicity. Myelosuppression (manifests as leucopenia, principally granulocytopenia); nausea & vomiting, abdominal pain, anorexia & diarrhea; reversible alopecia; hypotension following rapid IV infusion.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Etoposide Pfizer inj (vial) 20 mg/mL
5 mL x 1's;5 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in